ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Novellus Licenses Induced Mesenchymal Stem Cells to NoveCite for COVID-19 Related ARDS
October 19, 2020Novellus Therapeutics has licensed its induced mesenchymal stem cells (iMSCs) on a worldwide basis to NoveCite, a newly formed subsidiary of Citius Pharmaceuticals. -
Citius licences Novellus’ stem cell therapy for Covid-19-related ARDS
April 03, 2020Citius Pharmaceuticals has entered an exclusive six-month option agreement to licence a stem cell therapy from Novellus to treat acute respiratory distress syndrome (ARDS) related to Covid-19 infection. -
Citius, Novellus Ink COVID-19 Pact
April 02, 2020Citius to license novel stem-cell therapy for acute respiratory distress syndrome (ARDS) associated with COVID-19.
Pharma Sources Insight January 2025
